Metabolism:MAFLD与CKD风险

2020-11-17 MedSci原创 MedSci原创

MAFLD识别CKD患者的能力优于NAFLD。MAFLD和肝纤维化评分增加的MAFLD与CKD和蛋白尿密切相关。

非酒精性脂肪肝疾病(NAFLD)是一种多系统疾病,而代谢功能障碍相关性脂肪肝疾病(MAFLD)与肝外疾病之间的关联尚未明确。近日,代谢性疾病领域权威杂志Metabolism-Clinical and Experimental上发表了一篇研究文章,这项横断面研究旨在比较MAFLD或NAFLD患者慢性肾脏病(CKD)患病率,然后探究MAFLD和CKD的存在与严重程度与蛋白尿之间的关系。

研究人员分析了来自第三次全国健康和营养检查调查(1988-1994年)且具有完整生化和肝脏超声检查数据的12571名参与者。研究人员进行多变量logistic回归分析以评估MAFLD或MAFLD严重程度与关键暴露和CKD(定义为CKD≥1或≥3期)或蛋白尿(尿白蛋白与肌酐比值≥3mg/mmol)之间的相关性。

MAFLD和NAFLD的患病率分别为30.2%(n=3794)和36.2%(n=4552)。MAFLD患者的eGFR较低(74.96±18.21 vs. 76.46±18.24mL/min/1.73m2,P<0.001),CKD患病率较高(29.60% vs. 26.56%,P<0.05)。同样,与非代谢功能障碍相关的NAFLD相比,MAFLD患者的CKD患病率更高(P<0.05)。值得注意的是,在调整了性别、年龄、种族、饮酒量和糖尿病后,MAFLD的严重程度(即NAFLD纤维化评分≥0.676)与CKD患病风险增加1.34倍相关(P<0.05)。

由此可见,MAFLD识别CKD患者的能力优于NAFLD。MAFLD和肝纤维化评分增加的MAFLD与CKD和蛋白尿密切相关。

原始出处:

Dan-Qin Sun.et al.MAFLD and risk of CKD.Metabolism-Clinical and Experimental.2020.https://www.metabolismjournal.com/article/S0026-0495(20)30297-3/fulltext

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2083930, encodeId=e8e3208393094, content=<a href='/topic/show?id=d3b820e32c' target=_blank style='color:#2F92EE;'>#AFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2073, encryptionId=d3b820e32c, topicName=AFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Apr 03 23:42:12 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946241, encodeId=6abb194624137, content=<a href='/topic/show?id=6dd64802ee' target=_blank style='color:#2F92EE;'>#CKD风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4802, encryptionId=6dd64802ee, topicName=CKD风险)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqPdWFricgmt6Dde2ptNxJzD6Y9c4cxpXdTo4pNlVPARAnFdKu6nWIPele9icxApTaFgibq0uVlgRiceQ/132, createdBy=4b8c2500026, createdName=ms8435843352634314, createdTime=Wed Jul 28 13:42:12 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896777, encodeId=06701896e77b0, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Apr 11 20:42:12 CST 2021, time=2021-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888241, encodeId=8fc1188824103, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu May 13 00:42:12 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464231, encodeId=ffa91464231c1, content=<a href='/topic/show?id=9bc11123352' target=_blank style='color:#2F92EE;'>#MAFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11233, encryptionId=9bc11123352, topicName=MAFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c7b06623645, createdName=neizongke, createdTime=Thu Nov 19 01:42:12 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577244, encodeId=fe1815e72444a, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Thu Nov 19 01:42:12 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598081, encodeId=a72d159808103, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Thu Nov 19 01:42:12 CST 2020, time=2020-11-19, status=1, ipAttribution=)]
    2021-04-03 lvygwyt2781
  2. [GetPortalCommentsPageByObjectIdResponse(id=2083930, encodeId=e8e3208393094, content=<a href='/topic/show?id=d3b820e32c' target=_blank style='color:#2F92EE;'>#AFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2073, encryptionId=d3b820e32c, topicName=AFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Apr 03 23:42:12 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946241, encodeId=6abb194624137, content=<a href='/topic/show?id=6dd64802ee' target=_blank style='color:#2F92EE;'>#CKD风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4802, encryptionId=6dd64802ee, topicName=CKD风险)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqPdWFricgmt6Dde2ptNxJzD6Y9c4cxpXdTo4pNlVPARAnFdKu6nWIPele9icxApTaFgibq0uVlgRiceQ/132, createdBy=4b8c2500026, createdName=ms8435843352634314, createdTime=Wed Jul 28 13:42:12 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896777, encodeId=06701896e77b0, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Apr 11 20:42:12 CST 2021, time=2021-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888241, encodeId=8fc1188824103, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu May 13 00:42:12 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464231, encodeId=ffa91464231c1, content=<a href='/topic/show?id=9bc11123352' target=_blank style='color:#2F92EE;'>#MAFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11233, encryptionId=9bc11123352, topicName=MAFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c7b06623645, createdName=neizongke, createdTime=Thu Nov 19 01:42:12 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577244, encodeId=fe1815e72444a, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Thu Nov 19 01:42:12 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598081, encodeId=a72d159808103, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Thu Nov 19 01:42:12 CST 2020, time=2020-11-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2083930, encodeId=e8e3208393094, content=<a href='/topic/show?id=d3b820e32c' target=_blank style='color:#2F92EE;'>#AFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2073, encryptionId=d3b820e32c, topicName=AFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Apr 03 23:42:12 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946241, encodeId=6abb194624137, content=<a href='/topic/show?id=6dd64802ee' target=_blank style='color:#2F92EE;'>#CKD风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4802, encryptionId=6dd64802ee, topicName=CKD风险)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqPdWFricgmt6Dde2ptNxJzD6Y9c4cxpXdTo4pNlVPARAnFdKu6nWIPele9icxApTaFgibq0uVlgRiceQ/132, createdBy=4b8c2500026, createdName=ms8435843352634314, createdTime=Wed Jul 28 13:42:12 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896777, encodeId=06701896e77b0, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Apr 11 20:42:12 CST 2021, time=2021-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888241, encodeId=8fc1188824103, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu May 13 00:42:12 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464231, encodeId=ffa91464231c1, content=<a href='/topic/show?id=9bc11123352' target=_blank style='color:#2F92EE;'>#MAFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11233, encryptionId=9bc11123352, topicName=MAFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c7b06623645, createdName=neizongke, createdTime=Thu Nov 19 01:42:12 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577244, encodeId=fe1815e72444a, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Thu Nov 19 01:42:12 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598081, encodeId=a72d159808103, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Thu Nov 19 01:42:12 CST 2020, time=2020-11-19, status=1, ipAttribution=)]
    2021-04-11 一闲
  4. [GetPortalCommentsPageByObjectIdResponse(id=2083930, encodeId=e8e3208393094, content=<a href='/topic/show?id=d3b820e32c' target=_blank style='color:#2F92EE;'>#AFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2073, encryptionId=d3b820e32c, topicName=AFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Apr 03 23:42:12 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946241, encodeId=6abb194624137, content=<a href='/topic/show?id=6dd64802ee' target=_blank style='color:#2F92EE;'>#CKD风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4802, encryptionId=6dd64802ee, topicName=CKD风险)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqPdWFricgmt6Dde2ptNxJzD6Y9c4cxpXdTo4pNlVPARAnFdKu6nWIPele9icxApTaFgibq0uVlgRiceQ/132, createdBy=4b8c2500026, createdName=ms8435843352634314, createdTime=Wed Jul 28 13:42:12 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896777, encodeId=06701896e77b0, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Apr 11 20:42:12 CST 2021, time=2021-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888241, encodeId=8fc1188824103, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu May 13 00:42:12 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464231, encodeId=ffa91464231c1, content=<a href='/topic/show?id=9bc11123352' target=_blank style='color:#2F92EE;'>#MAFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11233, encryptionId=9bc11123352, topicName=MAFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c7b06623645, createdName=neizongke, createdTime=Thu Nov 19 01:42:12 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577244, encodeId=fe1815e72444a, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Thu Nov 19 01:42:12 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598081, encodeId=a72d159808103, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Thu Nov 19 01:42:12 CST 2020, time=2020-11-19, status=1, ipAttribution=)]
    2021-05-13 guojianrong
  5. [GetPortalCommentsPageByObjectIdResponse(id=2083930, encodeId=e8e3208393094, content=<a href='/topic/show?id=d3b820e32c' target=_blank style='color:#2F92EE;'>#AFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2073, encryptionId=d3b820e32c, topicName=AFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Apr 03 23:42:12 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946241, encodeId=6abb194624137, content=<a href='/topic/show?id=6dd64802ee' target=_blank style='color:#2F92EE;'>#CKD风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4802, encryptionId=6dd64802ee, topicName=CKD风险)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqPdWFricgmt6Dde2ptNxJzD6Y9c4cxpXdTo4pNlVPARAnFdKu6nWIPele9icxApTaFgibq0uVlgRiceQ/132, createdBy=4b8c2500026, createdName=ms8435843352634314, createdTime=Wed Jul 28 13:42:12 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896777, encodeId=06701896e77b0, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Apr 11 20:42:12 CST 2021, time=2021-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888241, encodeId=8fc1188824103, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu May 13 00:42:12 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464231, encodeId=ffa91464231c1, content=<a href='/topic/show?id=9bc11123352' target=_blank style='color:#2F92EE;'>#MAFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11233, encryptionId=9bc11123352, topicName=MAFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c7b06623645, createdName=neizongke, createdTime=Thu Nov 19 01:42:12 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577244, encodeId=fe1815e72444a, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Thu Nov 19 01:42:12 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598081, encodeId=a72d159808103, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Thu Nov 19 01:42:12 CST 2020, time=2020-11-19, status=1, ipAttribution=)]
    2020-11-19 neizongke
  6. [GetPortalCommentsPageByObjectIdResponse(id=2083930, encodeId=e8e3208393094, content=<a href='/topic/show?id=d3b820e32c' target=_blank style='color:#2F92EE;'>#AFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2073, encryptionId=d3b820e32c, topicName=AFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Apr 03 23:42:12 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946241, encodeId=6abb194624137, content=<a href='/topic/show?id=6dd64802ee' target=_blank style='color:#2F92EE;'>#CKD风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4802, encryptionId=6dd64802ee, topicName=CKD风险)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqPdWFricgmt6Dde2ptNxJzD6Y9c4cxpXdTo4pNlVPARAnFdKu6nWIPele9icxApTaFgibq0uVlgRiceQ/132, createdBy=4b8c2500026, createdName=ms8435843352634314, createdTime=Wed Jul 28 13:42:12 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896777, encodeId=06701896e77b0, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Apr 11 20:42:12 CST 2021, time=2021-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888241, encodeId=8fc1188824103, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu May 13 00:42:12 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464231, encodeId=ffa91464231c1, content=<a href='/topic/show?id=9bc11123352' target=_blank style='color:#2F92EE;'>#MAFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11233, encryptionId=9bc11123352, topicName=MAFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c7b06623645, createdName=neizongke, createdTime=Thu Nov 19 01:42:12 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577244, encodeId=fe1815e72444a, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Thu Nov 19 01:42:12 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598081, encodeId=a72d159808103, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Thu Nov 19 01:42:12 CST 2020, time=2020-11-19, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2083930, encodeId=e8e3208393094, content=<a href='/topic/show?id=d3b820e32c' target=_blank style='color:#2F92EE;'>#AFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2073, encryptionId=d3b820e32c, topicName=AFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Apr 03 23:42:12 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946241, encodeId=6abb194624137, content=<a href='/topic/show?id=6dd64802ee' target=_blank style='color:#2F92EE;'>#CKD风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4802, encryptionId=6dd64802ee, topicName=CKD风险)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqPdWFricgmt6Dde2ptNxJzD6Y9c4cxpXdTo4pNlVPARAnFdKu6nWIPele9icxApTaFgibq0uVlgRiceQ/132, createdBy=4b8c2500026, createdName=ms8435843352634314, createdTime=Wed Jul 28 13:42:12 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896777, encodeId=06701896e77b0, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Apr 11 20:42:12 CST 2021, time=2021-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888241, encodeId=8fc1188824103, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu May 13 00:42:12 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464231, encodeId=ffa91464231c1, content=<a href='/topic/show?id=9bc11123352' target=_blank style='color:#2F92EE;'>#MAFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11233, encryptionId=9bc11123352, topicName=MAFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c7b06623645, createdName=neizongke, createdTime=Thu Nov 19 01:42:12 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577244, encodeId=fe1815e72444a, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Thu Nov 19 01:42:12 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598081, encodeId=a72d159808103, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Thu Nov 19 01:42:12 CST 2020, time=2020-11-19, status=1, ipAttribution=)]
    2020-11-19 闆锋旦

相关资讯

Diabetes Care:2型糖尿病与骨折风险

该研究的结果没有表明诊断2型糖尿病后发生骨折的风险更高。在诊断出2型糖尿病后,应鼓励患者进行积极的生活方式改变,包括进行负重体育锻炼,以改善骨骼健康。

Stroke:饮酒方式和缺血性卒中风险

在特定饮酒方式的中年参与者中,缺血性卒中的风险降低,但仅限于早期。考虑到饮酒方式与缺血性卒中之间的长期联系,医师在对患者饮酒的教育方面应保持谨慎。

Brit J Cancer:血脂与大肠癌风险

调整肥胖指标后,血脂水平与大肠癌风险无关。甘油三酸酯和载脂蛋白A潜在的位点特异性效应需要进一步研究进行证实。

Neurology :历时12年研究发现,全职妈妈比职场女性记忆衰退更快,或导致更高老年痴呆风险

几乎没有人愿意长期甚至一辈子从事一种单调无味、缺少创造力的工作,因为这些工作可能代表着无薪或更低的薪水、更少的认知刺激,以及更低的社会参与感和经济安全感。

Neurology:血管紧张素II刺激性降压药与痴呆症风险

血管紧张素II刺激性降压药服用者比血管紧张素II抑制性降压药服用者痴呆症发生率更低。尽管亚组分析表明这并不会影响结局,但必须进一步检查适应症。

Neurology:娱乐活动参与度与痴呆症风险

在痴呆症的临床前阶段娱乐活动参与度有所下降。没有强有力的证据表明参加娱乐活动和痴呆之间存在保护性关联。